Investigating how tyrosine metabolism affects tuberculosis progression
The role of tyrosine metabolism in tuberculosis pathogenesis
This study is looking at how changes in a specific part of your body's metabolism might affect the progression of tuberculosis, and it's for people with TB or those at risk, to help find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11007255 on NIH RePORTER |
What this research studies
This research explores the role of tyrosine metabolism in the progression of tuberculosis (TB) disease. It examines how Mycobacterium tuberculosis (Mtb) alters the metabolism of immune cells, particularly focusing on the enzyme Fumarylacetoacetate hydrolase (FAH) and its impact on susceptibility to TB. By analyzing blood samples from individuals with TB and those at risk, the study aims to uncover metabolic changes that could inform new treatment strategies. The research employs genetic analysis and metabolic profiling to understand the relationship between tyrosine levels and TB disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to tuberculosis or are at risk of developing the disease, particularly those with genetic variations affecting tyrosine metabolism.
Not a fit: Patients who are not at risk for tuberculosis or do not have any metabolic disorders related to tyrosine metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that target metabolic pathways to prevent or treat tuberculosis.
How similar studies have performed: Previous research has indicated that metabolic interventions may play a significant role in managing tuberculosis, suggesting that this approach has potential based on earlier findings.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Suliman, Sara — University of California, San Francisco
- Study coordinator: Suliman, Sara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.